European Investment Bank’s €20 Million Financing Agreement With BioVersys

Pestalozzi advised the European Investment Bank (EIB) on all Swiss law aspects of this transaction.

The European Investment Bank (EIB), the lending arm of the European Union, and BioVersys AG, a privately-owned clinical-stage pharmaceutical company developing treatments for multidrug-resistant bacterial infections, announced the signing of a EUR 20 million venture debt transaction.

The financing supports the company’s research and development of a diverse pipeline of drugs that address antimicrobial resistance (AMR). AMR causes the majority of antimicrobial therapies to become obsolete. Due to its potential to trigger a new bacterial pandemic, AMR has been widely recognised as the top priority health threat by the WHO, G7 and G20.

The Pestalozzi team included Franz Schubiger (Picture), Nils Harbeke, Urs Kloeti, Daniela Fritsch and Severin Etzensperger.

Involved fees earner: Severin Etzensperger – Pestalozzi; Daniela Fritsch – Pestalozzi; Nils Harbeke – Pestalozzi; Urs Kloeti – Pestalozzi; Franz Schubiger – Pestalozzi;

Law Firms: Pestalozzi;

Clients: European Investment Bank;

Print Friendly, PDF & Email
Federica Tiefenthaler

Author: Federica Tiefenthaler